AstraZeneca Collaborates with mAbxience to Produce COVID-19 Vaccine in Latin America
Shots:
- mAbxience will produce ~200M + doses of AZD1222 and will supply it to all Latin American countries- except Brazil
- The company will produce API in its facility located in Garín (Argentina) and will send it to Mexico to complete the production and filling process. AstraZeneca will transfer its technology to the Garín plant shortly- allowing the facility to produce the vaccine in the coming months
- AstraZeneca’s AZD1222 has demonstrated robust immune response in its P-I & II studies- being evaluated in P-III study with its expected completion in the coming months. The vaccine is expected to be available in the H1’21- upon completion of the P-III trial and approval
Ref: mAbxience | Image: Thailand Medical News
Click here to read full press release/ article
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected]
